☆ 4.5 Review

Adverse Events of DOACs in Children

FRONTIERS IN PEDIATRICS (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Jacqueline Halton et al.

Summary: The study found that an age-adjusted and weight-adjusted dosing algorithm for dabigatran was effective in children with venous thromboembolism, showing similar pharmacokinetic-pharmacodynamic relationships to those seen in adults. In terms of efficacy, dabigatran was non-inferior to standard of care, indicating it may be a suitable alternative treatment option.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study

Brian W. McCrindle et al.

Summary: The UNIVERSE Study evaluated the efficacy and safety of liquid rivaroxaban versus acetylsalicylic acid in preventing thrombotic events in patients with single-ventricle physiology post-Fontan. The study found that participants receiving rivaroxaban had a better safety profile and fewer thrombotic events compared to those in the ASA group, although the difference was not statistically significant.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Hematology

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

Leonardo R. Brandao et al.

BLOOD (2020)

Add to Collection

Article Hematology

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

Christoph Male et al.

LANCET HAEMATOLOGY (2020)

Add to Collection

Review Health Care Sciences & Services

Management of Venous Thromboembolism in Children: Current Recommendations and Therapeutic Options

Alessandra Bosch et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)

Add to Collection

Review Education, Scientific Disciplines

Abnormal uterine bleeding in users of rivaroxaban and apixaban

Amanda E. Jacobson-Kelly et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)

Add to Collection

Article Hematology

Pathophysiology of thrombosis and anticoagulation post Fontan surgery

Chantal Attard et al.

THROMBOSIS RESEARCH (2018)

Add to Collection

Article Gastroenterology & Hepatology

Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial

Peter Bytzer et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

Sam Schulman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

Oral Rivaroxaban for Symptomatic Venous Thromboembolism.

Rupert Bauersachs et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Pediatrics

Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007

Leslie Raffini et al.

PEDIATRICS (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.